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ABSTRACT
The growth factor receptor tyrosine kinase (RTK) family is a potent inducer of cellular growth. Ligand binding to cognate receptors on plasma membrane induces receptor dimerization and activation, which in turn recruits intracellular molecules for downstream signal transduction. A
key signaling pathway activated by GF receptors is the Ras signaling cascade that ultimately leads to cell proliferation. Activation of RTKs leads to the recruitment of adapter protein Grb2, which is constitutively bound to the mammalian homologue of drosophila son of sevenless (SOS),
and a guanine exchange factor (GEF) for Ras. The recruitment of Grb2-SOS complex by activated RTK places the GEF at close proximity to Ras and exchange of Ras-GDP to Ras-GTP and the initiation of the mitogen-activated protein (MAP) kinase cascade. All RTKs recruit Grb2
either directly or indirectly to their early signaling complex as a means to activate Ras-MAP kinase signaling. Virtual drug screening has identified several dimer interface binding drug-like molecules bridging the two Grb2 protomers which severs the link to SOS that is critical to
Ras/MAP kinase activation. The design and synthesis of novel analogues to enhance binding and stabilization of dimeric Grb2 is presented.

BACKGROUND
Structurally Grb2 comprised of one central Src Homology2 (SH2) domain sandwiched
by two Src Homology3 (SH3) domains, one is N-terminal another one is Cterminal.[1]. When growth factor receptor such as epidermal growth factor receptor
(EGFR) binds to extracellular receptor of receptor tyrosine kinases (RTKs), leads to
dimerization as well as activation of kinases, resulting auto-phosphorylation of certain
tyrosine residue in the intracellular domains[2]. Through SH2 domain Grb2 interacts
with activated growth factor receptors either directly or indirectly with receptor
associated proteins (e.g., Shc, FAK, Syp and IRS-1), by recognizing specifically a
short pYXNX sequence motif [3] and this interaction translocate cytoplasmic Grb2SOS complex to the cell membrane, which brings SOS in the vicinity of membrane
anchored Ras and promote activation of Ras by changing Ras bound ADP for ATP[1].
The Grb2-SH2 domain basically demonstrates the presence of Grb2 as a dimeric state,
whereas the characterization of Grb2 as a monomer exist at the SH3 domain through
the proline-rich site [3]. The dissociate change of Grb2 dimerization state to
monomeric version occur due to the increase of tyrosine kinase activities in cytosol,
causing the reversible phosphatases actions which eventually led to the dissociation
[3]. In addition, mutants at the active monomeric Grb2 formations are more stable than
at the inactive Grb2 dimerization state(Fig 1), such as upon the phosphorylation of
tyrosine on Grb2-SH2 (Y160) residue [3]. Under other conditions, the Grb2
dimerization state plays a vital role to initiate and amplify rapid signal through RTKs
stimulation [1]. In this manner, the inhibition at the dimeric Grb2 can occur while the
promotion activities of Grb2 monomeric via the mitogen activated protein kinase
(MAPK) Pathway [2]. Thus, the synthesis of small non-peptide molecules to disable
the reversible dissociation process to monomer can shut down the Ras-MAPK
signaling pathway in cytosol.

utilizing three closely related templates; indolinone 2a, benzoxazolinone 2b,
benzimidazolone and 2c (Fig 2. B). We have prepared a large set of diverse ureas 4
were prepared by asimplistic acylation of readily available 2 with isocyantes 3. All
the compounds were purified by column chromatography and confirmed by LCMS,
H1 and C13 NMR. Analogues were isolated in moderate to high yield (55% - 85%).

100 nM Atto488 labeled Grb2 was used to identify compounds that induce dimerization,
where EC50 values represents corresponding Fluorescence anisotropy assay data of the
compound that induces dimerization function as opposite to binding affinity. Fig. 3 A shows a
representative anisotropy measurement of no-binding (NB) data for compound Grb038.
However, Fig. 3 B shows a representative anisotropy measurement with Grb093 inducing
Grb2 dimerization at a EC50 of 15.5 μΜ, where NB represents compounds inability to induce
Grb2 dimerization.
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Table 1. EC50 anisotropy data for dimeric Grb2
stabilizers. NB = No Binding; ND = Not determined.
Figure 3: A) NB anisotropy data for Grb038. B) Grb2 dimerization anisotropy data for
Grb093 at EC50 of 15.5 μΜ.

CONCLUSIONS
Fig 2: A) Screening hit 1. B) Representative urea analogues 4 synthesized.

RESULTS AND DISCUSSION

Figure 1: Green depicts homodimer with individual Grb2 protomers.[3]

METHODS
A virtual drug screen of 5000 compounds identified several dimer interface binding
drug-like molecules. The top 100 scoring compounds were assayed which resulted in
the identification of indolinone urea 1 as a Grb2 dimer stabilizer (Fig 2. A). To
explore the binding interface of the protein dimer we prepared a series of ureas

All compounds 4 were tested in HEK293T and NIH-3T3 cell-lines and a number
of cancer cell-lines including PC3, OVCAR-5 cells with G12V KRAS mutation.
OVCAR-8 contains ERBB2 G776V, p53 Y126 to K132 deletion and a rare P121H
KRAS mutation that display RAS/MAPK activation. Also found to be effective in
triple negative MDAMB- 231 breast cancer (TNBC) cells, which bears a G13D
KRAS as well as p53 mutations, and A549 lung cancer cells containing G12S
KRAS mutation. Expectedly, found that the stabilization of dimeric Grb2 leads to
inhibition of EGF-stimulated Ras/MAP without hampering the receptor tyrosine
kinase activity. Since dimeric Grb2 yields higher anisotropy value than the
monomeric Grb2, reflecting higher size of the molecule, the fluorescence
anisotropy assay was employed to measure the Grb2 dimerization.

In conclusion, our work suggests Grb2 dimer stabilizers may be useful chemical tools to
study EGFR and KRAS driven cancers. Interestingly, TNBC cells shows greater
sensitivity to the Grb2 dimer stabilizers and correlates with Ras/MAPK signal
transduction, paving the way for developing a novel strategy towards cancer therapy.
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